Skip to main content

Table 2 Associations between pathway alterations

From: Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

 

PTEN mut

PTEN wt

n

p

HER2+

HER2-

n

p

EGFR+

EGFR-

n

p

PIK3CA mut

PIK3CA wt

n

p

INPP4B low

INPP4B high

n

p

PTEN IHC-

3

20

103

0.010

2

23

107

0.117

14

11

107

<0.0001

1

24

107

0.012

6

11

85

0.111

PTEN IHC+

1

79

  

18

64

  

12

70

  

23

59

  

12

56

  

PTEN abrogation

    

2

24

107

0.098

14

12

107

<0.0001

2

24

107

0.072

6

12

85

0.155

PTEN normal

    

18

63

  

12

69

  

22

59

  

12

55

  

HER2+

        

8

14

110

0.150

6

17

113

0.871

3

15

91

0.624

HER2-

        

19

69

  

22

68

  

16

57

  

EGFR+

            

5

22

112

0.436

8

12

90

0.019

EGFR-

            

22

63

  

11

59

  

PIK3CA mut

                

4

24

94

0.281

PIK3CA wt

                

16

50

  
  1. Footnote: Significant p-values are indicated by bolding
  2. Abbreviations: mut mutant, wt wild-type
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us